Discussion On The Mechanism of Que In The Treatment of Breast Neoplasms And Immune Prevention And Treatment

Dan Qiu, Xianxin Yan, Xinqin Xiao, Guijuan Zhang, Yanqiu Wang, Jingyu Cao, Ruirui Ma, S.k. Hong, Min MaResearch 2021 · DOI

Summary

This study identifies Quercetin (Que), a common natural flavonoid, as a potent dual-action agent against breast cancer. It works by directly triggering apoptosis in cancerous and precancerous cells while simultaneously boosting the immune system's $\gamma\delta$ T cell response via the JAK/STAT1 signaling pathway.

The Challenge: Addressing Precancerous Breast Lesions

Breast cancer remains a leading cause of mortality among women globally. While traditional treatments like surgery and chemotherapy are standard, they often carry significant side effects and risk of recurrence. A critical gap in oncology is the management of precancerous lesions—the stage where non-neoplastic tissue is highly likely to transform into a tumor. There is an urgent need for low-toxicity, cost-effective compounds that can prevent this progression. This research investigates whether Quercetin, a dietary flavonoid found in many fruits and vegetables, can serve as a chemo-preventative and immunotherapeutic adjuvant.

Methodology: A Multi-Disciplinary Approach

The researchers employed a multi-disciplinary approach combining computational screening with traditional bench science. Using network pharmacology databases (such as PharmMapper and TCMSP), they identified the JAK/STAT1 pathway as a primary target for Quercetin. This was followed by in vitro testing using a progression model of cell lines: MCF-10A (normal-like), MCF-10AT (precancerous), and MCF-7/MDA-MB-231 (cancerous). To evaluate immune effects, $\gamma\delta$ T cells were isolated from human peripheral blood mononuclear cells (PBMCs) and co-cultured with breast cancer cells. Molecular changes were quantified using flow cytometry and Western blotting.

Key Insights: The "One-Two Punch" Mechanism

The study reveals that Quercetin acts as both a cytotoxic agent and an immunomodulator. It recruits the immune system by shifting the population of $\gamma\delta$ T cells toward the more aggressive $V\delta2$ subset, known for its potent anti-tumor activity.

Furthermore, Quercetin helps restore immune visibility. Cancer cells often "hide" from the immune system by expressing PD-L1, which deactivates T cells. This research demonstrates that Que significantly downregulates PD-L1 while upregulating the receptors (IFN$\gamma$-R) that make tumor cells more sensitive to immune-mediated death. This dual action—triggering apoptosis in precancerous cells while enhancing immune surveillance—suggests Que could stop tumors before they fully form.

Schematic representation of Quercetin's dual mechanism: inducing apoptosis in breast cancer cells and enhancing $\gamma\delta$ T cell-mediated immunity via the JAK/STAT1 pathway.

Experimental Results

  • Apoptosis Induction: Que induced significant, dose-dependent apoptosis across all cancerous and precancerous lines, with $IC_{50}$ values ranging from 52.39 $\mu$M to 64.23 $\mu$M.
  • Synergistic Killing: When $\gamma\delta$ T cells were combined with 5 $\mu$M of Que, the killing rate against breast cancer cells was significantly higher than with T cells alone, particularly at an effector-to-target ratio of 10:1.
  • Pathway Activation: Western blots confirmed that Que treatment led to a substantial increase in the phosphorylation of JAK2 and STAT1, alongside a statistically significant decrease in PD-L1 protein levels.

Limitations and Future Directions

While promising, these in vitro results require in vivo validation. The complex microenvironment of a living organism and Quercetin's notoriously poor systemic bioavailability remain hurdles. Future research must explore advanced delivery systems, such as nano-micelles, and conduct human trials to determine if the concentrations used in the lab are achievable and safe in patients.

Summary updated

Abstract

Abstract Background: The precancerous disease of breast cancer is an inevitable stage in the emergence and development of breast neoplasms. Breast cancer (BC) is a common malignant tumor in female worldwide. A large number of literatures have proved that, as antitumor drugs, flavonoid compounds can promote proliferation and immune regulation of T cell. Many researchers believe that Quercetin (Que) has great potential in the field of anti-breast cancer. Besides that, γδ T cells are a class of non-traditional T cells, which have long attracted attention due to their potential in immunotherapy. Above all, JAK/STAT1 signaling pathway is closely related to the immunity. Methods In the experiment designed in this paper, we first used Que, one of the flavonoids, to screen the target gene. Then, MCF-10A, MCF-10AT, MCF-7 and MDA-MB231 BC cells were co-cultured with Que for 24h and 48h, apoptosis was found in some the cells. We then cultured Que with γδ T cells and found that Que can promote the proliferation of Vδ2 T cell subsets of γδ T cells, thus enhancing the killing effect of γδ T cells. Western blot was use to showed the change of JAK/STAT1 signaling pathway related proteins after the Que was co-cultured with MCF-10AT and MCF-7 for 48h. Results Network pharmacology has shown that Que related pathways include the JAK/STAT1 signaling pathway and are associated with precancerous breast cancers. Que induced apoptosis of MCF-10AT, MCF-7 and MDA-MB-231 in a time and concentration-dependent manner. Most importantly, Que can promote the differentiation of γδ T cells into the Vδ2 T cell subpopulation, this means that Que and γδ T cells may play a synergistic role in killing tumor cells and cellular immune regulation. In addition, our results showed that Que can increase in protein levels of IFNγ-R, p-JAK2 and p-STAT1, while the concomitant decrease protein levels of PD-L1. Conclusions In conclusion, Que plays a synergistic role in killing BC cells and promoting apoptosis by regulating the expression of IFNγ-R, p-JAK2, p-STAT1, and PD-L1 in the JAK/STAT1 signaling pathway and promoting the regulation of γδ T cells. Que may be a potential drug for the prevention of precancerous breast cancer and adjuvant treatment of BC.
BibTeX
@inproceedings{qiu2021discussion,
  author = {Dan Qiu and Xianxin Yan and Xinqin Xiao and Guijuan Zhang and Yanqiu Wang and Jingyu Cao and Ruirui Ma and S.K. Hong and Min Ma},
  title = {{Discussion On The Mechanism of Que In The Treatment of Breast Neoplasms And Immune Prevention And Treatment}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-819024/v1},
}
Figure